Switching from Aspirin to Clopidogrel in Hematuria

Evidence Supporting the Switch

• The American Heart Association/American Stroke Association guidelines explicitly state that clopidogrel 75 mg daily is an acceptable alternative to aspirin for patients with cardiovascular disease, including those with contraindications to aspirin (Class I, Level A recommendation) 1, 2
• For patients with atherosclerotic disease in whom aspirin is contraindicated by factors other than active bleeding, clopidogrel 75 mg daily is a reasonable alternative (Class IIa, Level C) 1, 2

Clinical Decision Algorithm

• If the patient has recent acute coronary syndrome (<12 months), recent stroke/TIA (<12 months), or coronary stents within the mandatory dual antiplatelet therapy window: Continue aspirin but add proton pump inhibitor therapy and investigate hematuria source urgently 4
• If beyond mandatory dual antiplatelet therapy period or on aspirin for stable cardiovascular disease: Proceed with switch to clopidogrel 1, 2, 3

Critical Caveats and Pitfalls

• Never add clopidogrel to aspirin for routine management of hematuria, as the combination increases hemorrhage risk without reducing ischemic events in this context (Class III recommendation) 1, 2, 5
• If urologic surgery is needed, discontinue clopidogrel 5-7 days preoperatively and restart as soon as hemostasis is achieved postoperatively 6

Monitoring After the Switch

• No routine laboratory monitoring is required for clopidogrel, unlike warfarin 5
• Watch for rare thrombotic thrombocytopenic purpura (TTP), which can occur within the first 2 weeks of clopidogrel therapy 5